COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Onco-Innovations announces advancement in manufacturing partner's process development for proprietary PNKP inhibitor technology. Extension of engagement with MCS for market awareness services -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Onco-Innovations successfully scales up key intermediates A83 and B4, advancing its CMC program for nanoparticle-based PNKP inhibitor drug ONC010. Collaborates with Dalton Pharma Services for process optimization and future GMP manufacturing -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Onco-Innovations Limited announces advancement in analytical method for PNKP Inhibitor Technology, strengthening formulation development and scale-up for clinical manufacturing
